Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Ludek, Raida"'
Autor:
Axel Benner, Peter Dreger, Grzegorz W Basak, Christian Koenecke, Olaf Penack, Christophe Peczynski, Lucia López Corral, Ivan Moiseev, Hélène Schoemans, Zinaida Peric, Thomas Luft, Simona Sica, Mutlu Arat, Maija Itäla-Remes, Nicolaas P M Schaap, Michal Karas, Ludek Raida, Thomas Schroeder, Elisabetta Metafuni, Tulay Ozcelik, Brenda M Sandmaier, Lambros Kordelas
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background We previously reported that the “Endothelial Activation and Stress Index” (EASIX; ((creatinine×lactate dehydrogenase)÷thrombocytes)) measured before start of conditioning predicts mortality after allogeneic hematopoietic stem cell tr
Externí odkaz:
https://doaj.org/article/60017a9b556c4c1eaccc5b562a3da144
Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis
Autor:
Juan Carlos Hernandez Boluda, Dirk-Jan Eikema, Nadia Erazo, Nicolaus Kröger, Marie Robin, Moniek de Witte, Jürgen Finke, Alessandro Rambaldi, Annoek E.C. Broers, Ludek Raida, Nicolaas Schaap, Patrizia Chiusolo, Mareike Verbeek, Goda Choi, Kazimierz Halaburda, Alexander D. Kulagin, Helene Labussiere-Wallet, Tobias Gedde-Dahl, Werner Rabitsch, Kavita Raj, Joanna Drozd-Sokolowska, Nicola Polverelli, Tomasz Czerw, Ibrahim Yakoub-Agha, Donal P. McLornan
Publikováno v:
Blood. 140:10608-10610
Autor:
Adam Kuba, Ludek Raida
Publikováno v:
Mediators of Inflammation, Vol 2018 (2018)
Graft versus host disease (GVHD), a severe immunogenic complication of allogeneic hematopoietic stem cell transplantation (HSCT), represents the most frequent cause of transplant-related mortality (TRM). Despite a huge progress in HSCT techniques and
Externí odkaz:
https://doaj.org/article/8cc74fed7dde4cd88b7a30f50469dc9b
Autor:
Adam, Kuba, Ludek, Raida, Svetlana, Brychtova, Patrik, Flodr, Frantisek, Mrazek, Eva, Kriegova, Edgar, Faber, Tomas, Papajik
Publikováno v:
Transplant immunology. 76
Lower gastrointestinal (GI) graft versus host disease (GVHD) represents a severe complication in allogeneic hematopoietic stem cell transplant (HSCT) recipients with high rates of transplant-related mortality. Deregulated innate immunity reactions ar
Autor:
Adam Kuba, Ludek Raida, Patrik Flodr, Frantisek Mrazek, Eva Kriegova, Tomáš Papajík, Jiri Minarik
Publikováno v:
Blood. 140:7643-7644
Autor:
Tomas Papajik, Eva Kriegova, Frantisek Mrazek, Tomáš Fürst, Jana Furstova, Edgar Faber, Ludek Raida, Katerina Langova, Adam Kuba, Petra Schneiderova
Publikováno v:
Annals of Hematology. 99:609-618
Graft-versus-host disease (GVHD) represents a significant cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT). NF-kB system is a master regulator of innate immunity responses. It controls the expression of various cytok
Autor:
Frantisek Mrazek, Adam Kuba, Tomas Papajik, Ludek Raida, Edgar Faber, Eva Kriegova, Anna Petrackova
Publikováno v:
Transplantation and Cellular Therapy. 27:S278
Autor:
Tomáš Szotkowski, Alena Maluskova, Ivana Skoumalova, Ludek Raida, Zdenek Koristek, J. Onderkova, Frantisek Mrazek, Nikola Königova, Z. Ambruzova
Publikováno v:
International journal of immunogenetics. 45(6)
Loss of heterozygosity is considered to be the most common type of tumour-specific somatic mutation of the human leucocyte antigens (HLA) genes in patients with haematological malignancies. Nevertheless, subtle DNA sequence changes, namely short inse
Autor:
Ludek Raida, Adam Kuba
Publikováno v:
Mediators of Inflammation, Vol 2018 (2018)
Mediators of Inflammation
Mediators of Inflammation
Graft versus host disease (GVHD), a severe immunogenic complication of allogeneic hematopoietic stem cell transplantation (HSCT), represents the most frequent cause of transplant-related mortality (TRM). Despite a huge progress in HSCT techniques and
Autor:
Vít Procházka, Edgar Faber, Pavel Tuček, Tomas Papajik, Ludek Raida, Karel Indrak, Dana Cahova, Zuzana Rusinakova
Publikováno v:
Biomedical Papers. 158:428-432
Aims. A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment. Methods. A total of 194 patients were divided into